Buy 4-bromo-2 Cas 807631-09-0

Buy 4-bromo-2 Cas 807631-09-0

βk-2C-B, or bk-2C-B, also known as 4-bromo-2,5-dimethoxy-β-ketophenethylamine or as β-keto-2C-B, is a psychedelic drug of the phenethylamine and 2C family.^[3][1][2] It is the β-keto derivative of 2C-B.^[3][1] The drug is taken orally.^[1][2]

The drug acts as a very-low-potency serotonin 5-HT_2A receptor agonist.^[4][5]

βk-2C-B was first described in the scientific literature by Richard Glennon and colleagues in 2004.^[6] It was first encountered as a novel designer drug in Europe in 2013.^[7][3][1] The drug has since become a controlled substance in Canada, Germany, Switzerland, and the United Kingdom.^{[citation needed]}

βk-2C-B was not included nor mentioned in Alexander Shulgin‘s book PiHKAL (Phenethylamines I Have Known and Loved).^[8] However, it subsequently emerged as a novel recreational designer drug and its properties and effects were reported.^[1] βk-2C-B is usually taken orally, but may also be used by other routes.^[1][2] Insufflation is said to be not well-tolerated.^[1] The drug has been said to be used at doses of 150 to 1,000 mg orally.^[1] Its onset is said to be 20 to 70 minutes and its duration is said to be long at 10 to 40 hours.^[1] However, other sources have reported a dose range of 50 to 150 mg or more orally, an onset of 30 minutes, and a duration of 10 hours.^[2] The effects of βk-2C-B have been said to include euphoria, psychedelic visuals, entactogenic effects, and sensory enhancement, among others.^[1][2]

βk-2C-B acts as a very-low-potency serotonin 5-HT_2A receptor partial agonist.^[4][5] Its EC₅₀Tooltip half-maximal effective concentration was found to be 905 nM and its E_maxTooltip maximal efficacy was 41%.^[4] For comparison, 2C-B had an EC₅₀ of 9.0 nM and an E_max of 89% in the same study.^[4] In another study, βk-2C-B’s EC₅₀ at the serotonin 5-HT_2A receptor was 6,732 nM, compared to 0.28 nM in the case of 2C-I and 0.78 nM in the case of 2C-E (2C-B was not reported).^[5]

The interactions of βk-2C-B with monoamine oxidase (MAO) enzymes have been studied.^[9] Weak inhibition caused by βk-2C-B is evident at an IC₅₀Tooltip half-maximal inhibitory concentration of 14,000 nM for MAO-B whereas for MAO-A inhibition was undetectable.^[9]

βk-2C-B, also known as 4-bromo-2,5-dimethoxy-β-ketophenethylamine, is a substituted phenethylamine of the 2C family.^[1] It is the β-keto derivative of 2C-B.^[1]

The chemical synthesis of βk-2C-B has been described.^[6]

The thermal decomposition of βk-2C-B has been studied using a simulated ‘meth pipe’ scenario.^[10] Twelve major pyrolysis products were found for the thermally-induced decomposition of βk-2C-B.^[10]

Analogues of βk-2C-B include 2C-B, β-methyl-2C-B (BMB), BOB (β-methoxy-2C-B), and BOH-2C-B (BOHB; β-hydroxy-2C-B), among others.^[8]

βk-2C-B was first described in the scientific literature by Richard Glennon and colleagues in 2004.^[6] It was first encountered as a novel designer drug in Europe in 2013.^[7][3][1] In the years after its emergence on the market, papers reporting analytical characterizations of the substance appeared.^[3][11] Since October 2016, βk-2C-B has been a controlled substance in Canada.^[12] It is also illegal in Germany, Switzerland, and the United Kingdom.^{[citation needed]}

βk-2C-B is a controlled substance in the following countries:

• Canada: βk-2C-B is a Schedule III controlled substance as of October 12, 2016.^[12]
• Germany: βk-2C-B is controlled under the New Psychoactive Substances Act (NpSG) as of November 26, 2016. Possession is illegal but not penalized.^{[citation needed]}
• Sweden: βk-2C-B was classified as a narcotic on April 5, 2019.^[13]
• Switzerland: βk-2C-B is a controlled substance specifically named under Verzeichnis E.,^[14]
• United Kingdom: βk-2C-B is illegal to produce, supply or import under the Psychoactive Substance Act as of May 26, 2016.^[15]
• United States: βk-2C-B is unscheduled in the U.S.,^[16] but may be considered an analogue of 2C-B under the Federal Analogue Act, and thus a Schedule I drug if intended for human consumption.^{[citation needed]}